Nehmé Alissar, Edelman Jeffrey
Department of Biological Sciences, Allergan Inc., 2525 Dupont Drive, Irvine, CA 92612, USA.
Invest Ophthalmol Vis Sci. 2008 May;49(5):2030-8. doi: 10.1167/iovs.07-0273.
To characterize the effects of dexamethasone in human retinal pericytes (HRMPs), monocytes (THP-1), and retinal endothelial cells (HRECs) treated with high glucose, TNF-alpha, or IL-1beta.
HRMP and HREC phenotypes were verified by growth factor stimulation of intracellular calcium-ion mobilization. Glucocorticoid receptor phosphorylation was assessed with an anti-phospho-Ser(211) glucocorticoid receptor antibody. Secretion of 89 inflammatory and angiogenic proteins were compared in cells incubated with (1) normal (5 mM) or high (25 mM) D-glucose and (2) control medium, TNF-alpha (10 ng/mL), or IL-1beta (10 ng/mL), with or without dexamethasone (1 nM to 1 microM). The proteins were compared by using multianalyte profile testing.
HRMPs and HRECs expressed functional PDGFB-R and VEGFR-2, respectively. Dexamethasone induction of glucocorticoid receptor phosphorylation was dose-dependent in all cell types. High glucose increased secretion of inflammatory mediators in HRMPs, but not in HRECs. Dexamethasone dose dependently inhibited secretion of these mediators in HRMPs. For all cells, TNF-alpha and IL-1beta induced a fivefold or more increase in inflammatory and angiogenic mediators; HRMPs secreted the greatest number and level of mediators. Dexamethasone dose dependently inhibited the secretion of multiple proteins from HRMPs and THP-1 cells, but not from HRECs (IC(50) 2 nM to 1 microM).
High glucose, TNF-alpha, and IL-1beta induced an inflammatory phenotype in HRMPs, characterized by hypersecretion of inflammatory and angiogenic mediators. Dexamethasone at various potencies blocked hypersecretion of several proteins. Pericytes may be a key therapeutic target in retinal inflammatory diseases, including diabetic retinopathy. Inhibition of pathologic mediators may depend on delivering high levels ( approximately 1 microM) of glucocorticoid to the retina.
表征地塞米松对经高糖、肿瘤坏死因子-α(TNF-α)或白细胞介素-1β(IL-1β)处理的人视网膜周细胞(HRMPs)、单核细胞(THP-1)和视网膜内皮细胞(HRECs)的影响。
通过生长因子刺激细胞内钙离子动员来验证HRMP和HREC的表型。用抗磷酸化丝氨酸(211)糖皮质激素受体抗体评估糖皮质激素受体磷酸化。比较在(1)正常(5 mM)或高(25 mM)D-葡萄糖以及(2)对照培养基、TNF-α(10 ng/mL)或IL-1β(10 ng/mL)中培养的细胞,添加或不添加地塞米松(1 nM至1 μM)时89种炎症和血管生成蛋白的分泌情况。通过多分析物谱测试比较这些蛋白质。
HRMPs和HRECs分别表达功能性血小板衍生生长因子B受体(PDGFB-R)和血管内皮生长因子受体-2(VEGFR-2)。地塞米松诱导的糖皮质激素受体磷酸化在所有细胞类型中均呈剂量依赖性。高糖增加了HRMPs中炎症介质的分泌,但在HRECs中未增加。地塞米松剂量依赖性地抑制了HRMPs中这些介质的分泌。对于所有细胞,TNF-α和IL-1β诱导炎症和血管生成介质增加五倍或更多;HRMPs分泌的介质数量和水平最高。地塞米松剂量依赖性地抑制HRMPs和THP-1细胞中多种蛋白质的分泌,但不抑制HRECs(半数抑制浓度(IC50)为2 nM至1 μM)。
高糖、TNF-α和IL-1β在HRMPs中诱导出炎症表型,其特征为炎症和血管生成介质的过度分泌。不同效力的地塞米松可阻断几种蛋白质的过度分泌。周细胞可能是包括糖尿病性视网膜病变在内的视网膜炎症性疾病的关键治疗靶点。抑制病理性介质可能依赖于向视网膜递送高水平(约1 μM)的糖皮质激素。